Patent ID: 7514086
Filing Date: 2009-04-07
Classification: A61K,A61P,C12N

Abstract:
1. A human synthetic peptide-based influenza vaccine comprising at least four epitopes of influenza virus, said influenza virus epitopes being reactive with human cells, wherein said epitopes comprise: (i) the influenza virus B-cell hemagglutinin (HA) epitope HA 91-108 of the sequence: Ser-Lys-Ala-Phe-Ser-Asn-Cys-Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-Ser-Leu (SEQ ID NO:1); (ii) one T-helper hemagglutinin (HA) or nucleoprotein (NP) epitope that can bind to many HLA molecules, wherein said T-helper epitope is selected from the group consisting of influenza virus hemagglutinin epitope HA 307-319 of the sequence: Pro-Lys-Tyr-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala-Thr (SEQ ID NO:2) and the HA epitope HA 306-324 of the sequence: Cys-Pro-Lys-Tyr-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala-Thr-Gly-Met-Arg-Asn-Val (SEQ ID NO:3); and (iii) at least two cytotoxic lymphocyte (CTL) nucleoprotein (NP), matrix protein (M), or hemagglutinin (HA) epitopes that are restricted to the most prevalent HLA molecules in different human populations, and wherein each said epitope is individually expressed in a